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The application of the live vi-
rus vaccines for prevention of upper 
respiratory tract infections began in the 
70s and gave rise to favourable changes 
during the mumps and morbilli epi-
demic process (1,6). The incidence rate 
sharply decreased when compared with 
the that in the preimmunization period, 
the seasonal character of the diseases 
was outlined if even at a considerably 
lower level, and the interval between 
the epidemic years was prolonged. 
Along with these favourable trends, 
some disadvantageous ones arised, the 
reasons of which being of a complex 
nature. 
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We aimed at determining some 
important epidemiologic features of the 
mumps epidemic process in the last two 
epidemic years with a view of a mass 
immunoprevention by a live anti-paroti-
tis vaccine and at indicating some 
programme tasks, the success of the 
mass immunoprevention depending on 
their solution. 
MATERIAL AND METHODS 
The results of an epidemiologic 
study of the incidence rate of mumps 
in 1997-1998 in the region of Varna 
were used. Data from the reported cases 
of mumps in the listings of the Hygienic 
and Epidemiologic Inspection of Varna 
were analyzed. These sources were pro-
cessed by means of statistical analyses 
and epidemiological methods. 
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K e y - w o r d s : Epidemic parotitis, mass immunoprevention, live vaccine, incidence 
rate, Varna region 
R. Konstantinov et al. 
RESULTS AND DISCUSSION 
During the two years covered a 
total of 3694 mumps cases were regis­
tered. In 1997, there were 1724 cases 
(381,77 per 100 000 inhabitants) but in 
1998 there were 1970 ones (436,24 per 
100 000 inhabitants). The analysis of 
the epidemic situation and of the inci­
dence rate of the parotitis in Bulgaria 
focused on the beginning of a new epi­
demic wave with extremely high preva­
lence of the disease in North-Eastern 
Bulgaria (4). The process arose after 9 
years of fading because of a mass im­
munization by anti-parotitis vaccine. 
The distribution of the mumps 
incidence rates according to the age 
groups was demonstrated on Fig. 1. It 
was evident that during these two epi­
demic year the age group between 9 and 
14 years showed the highest values: 
2337,9 cases per 100 000 inhabintants 
in 1997 and 2389 cases per 100 000 
inhabitants in 1998. The situation con­
cerning the morbidity rates in these two 
years was similar (Fig. 2). The ill chil­
dren aged between 1 and 7 years dem­
onstrated a great difference in their dis­
tribution when the post- and pre-immu-
nization periods were covered (1,5-7). 
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Fig. 1. Age structure of the epidemic parotitis incidence rate in Varna region in 1997and 1998 











Fig. 2. Age distribution of the epidemic parotitis patients in Varna region in 1997 and 1998 
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ould be explained by the changes of 
"ie parotitis epidemiological patterns 
during the years of the mass 
immunoprevention by a live anti-paroti­
tis vaccine. The investigations of the 
immune status of the Bulgarian popu­
lation revealed a great delay of cover­
ing with the anti-parotitis vaccine, es­
pecially of the school children aged be­
tween 10 and 14 years (4). It was caused 
by the cancelled immunization mea-
ures during the period from 1982 till 
1984. Campaign corrective immuniza-
ions failed, obviously, to cover com­
pletely and timely the children subjected 
о immunization during the period with­
out any immunization against mumps. 
The analysis of the years of the 
pre-epidemic period (3) explained the 
reasons for the present epidemic situa­
tion. It was established that in this pe­
riod the 1-10-year old children got the 
mumps more often (71 % ) as compared 
with the school children aged between 
10 and 14 years (13,7 % ) . During the 
sero-epidemic investigations a low level 
of protection against the disease in the 
• men 
• women 
Fig. 3. Epidemic parotitis patients1 distribution 
sex and residence 
age of 20-30 years was found. The 
school children and military staff were 
more often affected than other contin­
gents. These results showed that in the 
years of a continuous pre-epidemic pe­
riod acceptable contingents were 
formed between the older groups due 
to the collective actions of some orga­
nizations and to social reasons as well. 
There was a situation when under con­
ditions of teams of subjects formed by 
these age groups the epidemic process 
originated. This fact was epidemiologi-
cally determined (1,5,7). 
The male sex and the urban 
population were predominantly affected 
(Fig. 3). Most cases were registered 
during the winter-spring period (Fig. 4) 
that was in accordance with the epi­
demic features of mumps. The immune 
status of the patients with parotitis in­
dicated that the individuals with un­
known immune status dominated (69 
% ) over those with previous immuni­
zation in childhood (31 % of the cases). 
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Fig. 4. Seasonal dynamics of the epidemic parotitis incidence rate in Varna region in 1997 and 1998 
The incidence rate among the 
immunized contingents can be related 
with the qualities of the biological prod-
ucts used. In the beginning, a Bulgar-
ian NCZPB vaccine was applied but 
later on a Russian live anti-parotitis 
vaccine was administered (1,8) which 
replaced the morbilli-parotitis-rubeola 
tri-vaccine. 
There are antagonistic points of 
view in the Russian literature available 
(9) about the qualities of the mumps 
vaccine we have made use of. It is sure 
there are problems because they recog-
nize the need of renewing the biologi-
cal product and of reducing it to meet 
the requirements of the WHO. These 
facts together with the organizational 
aspects give proof of the epidemic pro-
cess development in the aged groups. 
Some 287 patients out of a total 
of 3,694 ones during the two epidemic 
years were hospitalized in the Clinic of 
Infectious Diseases, Medical University 
of Varna, as cases with severe clinical 
course of parotitis. The percentage of 
the patients with complicated course of 
the disease in Bulgaria was smaller (3,2 
% ) (4). This is explained by the higher 
parotitis incidence rate in the region of 
Varna. Some 112 patients (39,02 % of 
all the hospitalized cases) presented 
with another localization of the patho-
logical process such as meningitis, or-
chitis, pancreatitis and lesion of the 
acoustic nerve. 
The epidemiological analysis of 
the morbidity rate of parotitis during the 
last two epidemic years indicates that a 
large prophylaxis programme should be 
realized to get the correct epidemic sta-
tus. The following measures have to be 
accomplished: 
l.To investigate the immune 
status of the risk age groups as a result 
of immunizations by various vaccines. 
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2. To identify the quality and ef­
fectiveness of the live anti-parotitis vac­
cine currently used and to show the 
• immunized 
• no immunization data 
ig. 5. Relative share of persons immunized by 
nti-mumps vaccine among the parotitis pa-
'ents in Varna region in 1997 and 1998 
opportunity for eradication of the 
mumps virus. 
3. To examine the correlation 
between the immunization and naturally 
existing epidemic process. 
4. To up-date the immunization 
calender (8) by introducing a re-immu­
nization schedule by morbilli-parotitis-
rubeola tri-vaccine, eventually at the 
age of 7 and 11-12 years thus observ­
ing the recommendations of the experts 
of the Centers for Disease Control and 
Prevention (Atlanta, GA, USA) as ap­
plicable in Bulgaria (10). 
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Р е з ю м е : Анализират се особеностите на епидемиологичния процес при епидемичния 
паротит в условията на масова имунопрофилактика. Установява се увеличаване 
честотата на заболяванията с отдалечаване от първичната имунизация с жива 
противопаротитна ваксина. Разглеждат се някои възможности за подобряване на 
епидемиологичния контрол при тази ваксино-предотвратима инфекция. 
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